COVID-19 Impact on Global Gene Therapy for CNS Disorders Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Gene Therapy for CNS Disorders Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Gene Therapy for CNS Disorders Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Ex Vivo
  • 1.4.3 In Vivo
• 1.5 Market by Application
  • 1.5.1 Global Gene Therapy for CNS Disorders Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Others
• 1.6 Coronavirus Disease 2019 (Covid-19): Gene Therapy for CNS Disorders Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Gene Therapy for CNS Disorders Industry
    • 1.6.1.1 Gene Therapy for CNS Disorders Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Gene Therapy for CNS Disorders Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Gene Therapy for CNS Disorders Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Gene Therapy for CNS Disorders Market Perspective (2015-2026)
• 2.2 Gene Therapy for CNS Disorders Growth Trends by Regions
  • 2.2.1 Gene Therapy for CNS Disorders Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Gene Therapy for CNS Disorders Historic Market Share by Regions (2015-2020)
  • 2.2.3 Gene Therapy for CNS Disorders Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Gene Therapy for CNS Disorders Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Gene Therapy for CNS Disorders Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Gene Therapy for CNS Disorders Players by Market Size
  • 3.1.1 Global Top Gene Therapy for CNS Disorders Players by Revenue (2015-2020)
  • 3.1.2 Global Gene Therapy for CNS Disorders Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Gene Therapy for CNS Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Gene Therapy for CNS Disorders Market Concentration Ratio
  • 3.2.1 Global Gene Therapy for CNS Disorders Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Gene Therapy for CNS Disorders Revenue in 2019
• 3.3 Gene Therapy for CNS Disorders Key Players Head office and Area Served
• 3.4 Key Players Gene Therapy for CNS Disorders Product Solution and Service
• 3.5 Date of Enter into Gene Therapy for CNS Disorders Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Gene Therapy for CNS Disorders Historic Market Size by Type (2015-2020)
• 4.2 Global Gene Therapy for CNS Disorders Forecasted Market Size by Type (2021-2026)

5 Gene Therapy for CNS Disorders Breakdown Data by Application (2015-2026)

• 5.1 Global Gene Therapy for CNS Disorders Market Size by Application (2015-2020)
• 5.2 Global Gene Therapy for CNS Disorders Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Gene Therapy for CNS Disorders Market Size (2015-2020)
• 6.2 Gene Therapy for CNS Disorders Key Players in North America (2019-2020)
• 6.3 North America Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 6.4 North America Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Gene Therapy for CNS Disorders Market Size (2015-2020)
• 7.2 Gene Therapy for CNS Disorders Key Players in Europe (2019-2020)
• 7.3 Europe Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 7.4 Europe Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

8 China

• 8.1 China Gene Therapy for CNS Disorders Market Size (2015-2020)
• 8.2 Gene Therapy for CNS Disorders Key Players in China (2019-2020)
• 8.3 China Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 8.4 China Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Gene Therapy for CNS Disorders Market Size (2015-2020)
• 9.2 Gene Therapy for CNS Disorders Key Players in Japan (2019-2020)
• 9.3 Japan Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 9.4 Japan Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Gene Therapy for CNS Disorders Market Size (2015-2020)
• 10.2 Gene Therapy for CNS Disorders Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 10.4 Southeast Asia Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

11 India

• 11.1 India Gene Therapy for CNS Disorders Market Size (2015-2020)
• 11.2 Gene Therapy for CNS Disorders Key Players in India (2019-2020)
• 11.3 India Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 11.4 India Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Gene Therapy for CNS Disorders Market Size (2015-2020)
• 12.2 Gene Therapy for CNS Disorders Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 12.4 Central & South America Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Gilead (Kite Pharma)
  • 13.1.1 Gilead (Kite Pharma) Company Details
  • 13.1.2 Gilead (Kite Pharma) Business Overview and Its Total Revenue
  • 13.1.3 Gilead (Kite Pharma) Gene Therapy for CNS Disorders Introduction
  • 13.1.4 Gilead (Kite Pharma) Revenue in Gene Therapy for CNS Disorders Business (2015-2020))
  • 13.1.5 Gilead (Kite Pharma) Recent Development
• 13.2 Amgen (BioVex)
  • 13.2.1 Amgen (BioVex) Company Details
  • 13.2.2 Amgen (BioVex) Business Overview and Its Total Revenue
  • 13.2.3 Amgen (BioVex) Gene Therapy for CNS Disorders Introduction
  • 13.2.4 Amgen (BioVex) Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
  • 13.2.5 Amgen (BioVex) Recent Development
• 13.3 Novartis
  • 13.3.1 Novartis Company Details
  • 13.3.2 Novartis Business Overview and Its Total Revenue
  • 13.3.3 Novartis Gene Therapy for CNS Disorders Introduction
  • 13.3.4 Novartis Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
  • 13.3.5 Novartis Recent Development
• 13.4 Roche (Spark Therapeutics)
  • 13.4.1 Roche (Spark Therapeutics) Company Details
  • 13.4.2 Roche (Spark Therapeutics) Business Overview and Its Total Revenue
  • 13.4.3 Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Introduction
  • 13.4.4 Roche (Spark Therapeutics) Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
  • 13.4.5 Roche (Spark Therapeutics) Recent Development
• 13.5 Bluebird Bio
  • 13.5.1 Bluebird Bio Company Details
  • 13.5.2 Bluebird Bio Business Overview and Its Total Revenue
  • 13.5.3 Bluebird Bio Gene Therapy for CNS Disorders Introduction
  • 13.5.4 Bluebird Bio Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
  • 13.5.5 Bluebird Bio Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer